Here is what we have been writing.Setting standards in the CRISPR genome editing revolution Samantha Maragh from the NIST (US National Institute of Standards and Technology) gives us the lowdown on finding standards and best-practices in the new and quickly evolving field of CRISPR medicine CRISPR - an exciting gene therapy journey is on the way and it is fine. Kevin Holden, head of science at Synthego corporation based in Silicon Valley, shares his thoughts on the beginning of CRISPR medicine and on automation and large data-sets as a way to best practices in gene editing. Safety considerations for delivering CRISPR Cas9 medicines. It's all about safety - an interview with safety director at AstraZeneca, Roberto Nitsch, about the key safety aspects of delivering potential CRISPR-medicine to patients. CRISPR revolution enabled by these key breakthroughs, and why TALENs could make a comeback. Well considered thoughts on "the sharing of science" from Jason Potter of Thermofisher and the breakthroughs that led to the CRISPR revolution. |